Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pittel

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
European Journal of Pharmacology|February 22, 1996
Pharmacological basis for functional selectivity of partial muscarinic receptor agonistsE Heldman, J Barg, A Fisher, et al.
Neuroscience Letters|July 31, 1989
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsA Fisher, R Brandeis, Z Pittel, et al.
Journal of Neurochemistry|November 3, 1998
Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretionR Haring, A Fisher, D Marciano, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|May 13, 2016
Wireless Vital Sign Monitoring in Pregnant Women: A Functionality and Acceptability StudyAdeline Adwoa Boatin, Blair Johnson Wylie, Ilona Goldfarb, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's diseaseA Fisher, R Brandeis, I Karton, et al.
Advances in Neurology|January 1, 1990
AF102B: rational treatment strategy for Alzheimer's disease: recent advancesA Fisher, R Brandeis, I Karton, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|January 16, 2020
Pediatric diabetic retinopathy telescreeningSasha Strul, Yuxi Zheng, Sapna Gangaputra, et al.
Annals of the New York Academy of Sciences|December 29, 1995
Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cellsH D Danenberg, R Haring, E Heldman, et al.
Journal of Molecular Neuroscience : MN|September 6, 2002
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's diseaseAbraham Fisher, Rachel Brandeis, Rachel Haring Nira Bar-Ner, et al.
Patient Education and Counseling|July 27, 2014
Development and validation of the diabetes adolescent problem solving questionnaireShelagh A Mulvaney, Sarah S Jaser, Russell L Rothman, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
European Journal of Pharmacology|February 22, 1996
Pharmacological basis for functional selectivity of partial muscarinic receptor agonistsE Heldman, J Barg, A Fisher, et al.
Neuroscience Letters|July 31, 1989
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsA Fisher, R Brandeis, Z Pittel, et al.
Journal of Neurochemistry|November 3, 1998
Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretionR Haring, A Fisher, D Marciano, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|May 13, 2016
Wireless Vital Sign Monitoring in Pregnant Women: A Functionality and Acceptability StudyAdeline Adwoa Boatin, Blair Johnson Wylie, Ilona Goldfarb, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's diseaseA Fisher, R Brandeis, I Karton, et al.
Advances in Neurology|January 1, 1990
AF102B: rational treatment strategy for Alzheimer's disease: recent advancesA Fisher, R Brandeis, I Karton, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|January 16, 2020
Pediatric diabetic retinopathy telescreeningSasha Strul, Yuxi Zheng, Sapna Gangaputra, et al.
Annals of the New York Academy of Sciences|December 29, 1995
Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cellsH D Danenberg, R Haring, E Heldman, et al.
Journal of Molecular Neuroscience : MN|September 6, 2002
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's diseaseAbraham Fisher, Rachel Brandeis, Rachel Haring Nira Bar-Ner, et al.
Patient Education and Counseling|July 27, 2014
Development and validation of the diabetes adolescent problem solving questionnaireShelagh A Mulvaney, Sarah S Jaser, Russell L Rothman, et al.
Pageof 7